Table 2. Completion of treatment in 210 patients with LA NPC.
Treatment | N (%) |
---|---|
NAC regimens | |
TPF | 62 (29.5) |
TP | 64 (30.5) |
GP | 7 (3.3) |
FP | 73 (34.8) |
Other | 4 (1.9) |
Cycle of NAC | |
1 | 40 (19.0) |
2 | 80 (38.1) |
3–4 | 90 (42.9) |
CC regimens | |
Cisplatin | 198 (94.3) |
Non-cisplatin | 12 (5.7) |
Cycle of CC | |
1 | 76 (36.2) |
2 | 120 (57.1) |
≥3 | 14 (6.7) |
Period of CC | |
Weekly | 12 (5.7) |
3 weeks | 198 (94.3) |
AC | |
No | 115 (54.8) |
Yes | 95 (45.2) |
Fractional dose of h-R3 | |
100 mg | 23 (11.0) |
200 mg | 187 (89.0) |
Total dose of h-R3 | |
< 1200 mg | 60 (28.6) |
≥ 1200 mg | 150 (71.4) |
Cycle of h-R3 | |
< 6 weeks | 39 (18.6) |
≥ 6 weeks | 171 (81.4) |
Abbreviations: NAC: neoadjuvant chemotherapy. CC: concurrent chemotherapy. AC: adjuvant chemotherapy. h-R3: nimotuzumab.